North America Biopharmaceuticals Market Trends, Size, Segment and Growth by Forecast to 2030

North America Biopharmaceuticals Market Overview

The North America biopharmaceuticals market was valued at US$ 151.22 billion in 2022 and is projected to reach US$ 315.74 billion by 2028, growing at a CAGR of 13.1% from 2022 to 2028. The market expansion is driven by advancements in biotechnology, increasing investment in research and development (R&D), and the rising prevalence of chronic diseases.

Potential to Treat Rare Diseases Driving Market Growth

According to the National Institutes of Health (NIH), 30 million Americans (approximately 10% of the U.S. population) are affected by one of the ~7,000 known rare diseases. Despite the complexities associated with developing treatments for these diseases, biopharmaceutical researchers in North America have made significant strides in pioneering innovative therapies. Over the past decade, the U.S. Food and Drug Administration (USFDA) has approved over 350 orphan drugs, primarily targeting conditions with limited or no treatment options.

One notable example is transthyretin amyloid cardiomyopathy (ATTR-CM), a rare cardiovascular disease that significantly reduces life expectancy if left untreated. Additionally, Ultragenyx Pharmaceutical Inc. is conducting safety testing and dosage determination for UX053, a potential first-in-class treatment for Glycogen Storage Disease (GSD) Type 3. The company’s mRNA-based therapy aims to deliver large genes to targeted cells for enhanced protein expression, with customized dosing strategies for patient-specific treatments. These advancements, along with regulatory approvals, are contributing to the rapid growth of the North American biopharmaceutical market.

North America Biopharmaceuticals Report Scope

Market Dynamics and Strategic Insights

The North America biopharmaceuticals market encompasses the United States, Canada, and Mexico, with the U.S. leading in market share due to strong R&D investment, regulatory support, and technological advancements. Biopharmaceuticals are revolutionizing the treatment of debilitating diseases such as Alzheimer’s, cancer, heart disease, and hepatitis C.

Key factors fueling market growth include:

• High Incidence of Chronic Diseases: According to the Centers for Disease Control and Prevention (CDC), 20.1 million adults in the U.S. suffer from coronary artery disease (CAD), with a heart attack occurring every 40 seconds.
• R&D Investment and Innovation: U.S. biopharmaceutical companies account for nearly 50% of global drug development, with over 3,400 drugs in clinical trials as of 2020.
• Economic Contributions: The industry significantly impacts the economy, with pharmaceutical and medical manufacturing contributing 0.95% to private-sector value in 2018, while biotech R&D facilities added 0.23%.

Regional Market Insights

Understanding regional market dynamics is crucial for businesses to tailor their strategies effectively. Key regional insights include:

• United States: Dominates the market due to a robust biopharmaceutical ecosystem, strong regulatory support, and substantial R&D investment.
• Canada: Growing investment in biotech and pharmaceutical research, particularly in oncology and rare diseases.
• Mexico: Emerging as a key market with increasing government support for pharmaceutical innovation and clinical trials.
  
  𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 – https://www.businessmarketinsights.com/sample/BMIRE00028630

Market Segmentation

By Product Type:

• Monoclonal Antibodies (Largest Segment in 2022)
• Recombinant Vaccines (Cancer, Malaria, Hepatitis-B, Tetanus, Diphtheria, Cholera, etc.)
• Conventional Vaccines (Polio, Pox, etc.)
• Recombinant Growth Factors (Erythropoietin, Granulocyte Colony-Stimulating Factor)
• Purified Proteins (Leukemia Inhibitory Factor, P53 Protein, etc.)
• Recombinant Proteins (Serum Albumin, Amyloid Protein, etc.)
• Recombinant Hormones (Human Growth Hormones, Insulin, etc.)
• Recombinant Enzymes (Enterokinase, Cyclase, Caspase, etc.)
• Cell & Gene Therapies (Allogenic, Autologous, Acellular Products)
• Cytokines/Interferon/Interleukins

By Application:

• Oncology (Largest Segment in 2022)
• Inflammatory & Infectious Diseases
• Autoimmune Disorders
• Metabolic Disorders
• Hormonal Disorders & Growth Failure
• Cardiovascular Diseases
• Neurological Diseases

Leading Companies in North America Biopharmaceuticals Market

Key players shaping the industry include:

• AbbVie Inc.
• AGC Biologics AS
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• Eli Lilly and Co.
• Johnson & Johnson
• Lonza Group AG
• Thermo Fisher Scientific Inc.
• WuXi Biologics Inc.

Conclusion

The North America biopharmaceuticals market is experiencing significant expansion, driven by technological advancements, increased R&D investments, and a rising demand for innovative treatments. With a strong focus on rare disease therapies, oncology treatments, and gene-based innovations, the market is poised for sustained growth. Companies operating in this sector must leverage regional insights, strategic market segmentation, and robust research initiatives to maintain a competitive edge in this evolving landscape.

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Défense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications

Author’s Bio:
Akshay
Senior Market Research Expert at Business Market Insights